Publication date: Dec 06, 2019
These are the first generics of the drug, which treats relapsing forms of multiple sclerosis (MS) in adult patients. The approvals were granted to HEC PharmD Co. Limited, Biocon Limited, and Sun Pharmaceutical Industries Limited. MS is a chronic, inflammatory autoimmune disease that disrupts communication between the brain and other parts of the body. It is one of the most common causes of neurological disability in young adults. According to the National Multiple Sclerosis Society, the disease is believed to affect nearly 1 million adults in the United States.